Vaccizone

Vaccizone is a Turkish biotechnology company focused on developing innovative vaccines and immunotherapies using its proprietary ASC-speck delivery platform. The technology leverages the ASC (Apoptosis-associated speck-like protein containing a CARD) protein to create bio-compatible nanoparticles that effectively deliver antigens and stimulate robust immune responses. The company's lead program is a COVID-19 vaccine candidate that has entered clinical trials, while its oncology pipeline targets difficult-to-treat conditions such as glioblastoma and breast cancer. Vaccizone aims to provide scalable, cost-effective, and highly stable therapeutic solutions for global health challenges.